Indian drugmakers adopt 'wait-and-watch' on US expansion amid tariff talks

Indian pharmaceutical manufacturers are holding back on significant new investments in US production facilities despite the prospect of higher American tariffs on Chinese goods. Citing high costs and regulatory uncertainty, firms are adopting a cautious 'wait-and-watch' strategy. They continue to primarily serve the US market from their manufacturing bases in India.